PLoS Pathogens · 2013 · 122 citations · 33 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyAntibody-mediated ProtectionHumoral ImmunityInactivated VaccinesVaccinationVaccine PlatformsViral VaccinesAntibodiesAntibody SubclassesEbola VaccinesRabies VaccinesRabies VirusSafety Of Inactivated VaccinesSubunit Vaccine ImmunogenicityViral Immune Responses
We have previously described the generation of a novel Ebola virus (EBOV) vaccine platform based on (a) replication-competent rabies virus (RABV), (b) replication-deficient RABV, or (c) chemically inactivated RABV expressing EBOV glycoprotein (GP). Mouse studies demonstrated safety, immunogenicity, and protective efficacy of these live or inactivated RABV/EBOV vaccines. Here, we evaluated these vaccines in nonhuman primates. Our results indicate that all three vaccines do induce potent immune responses against both RABV and EBOV, while the protection of immunized animals against EBOV was largely dependent on the quality of humoral immune response against EBOV GP. We also determined if the induced antibodies against EBOV GP differ in their target, affinity, or the isotype. Our results show that IgG1-biased humoral responses as well as high levels of GP-specific antibodies were beneficial for the control of EBOV infection after immunization. These results further support the concept that a successful EBOV vaccine needs to induce strong antibodies against EBOV. We also showed that a dual vaccine against RABV and filoviruses is achievable; therefore addressing concerns for the marketability of this urgently needed vaccine.
33
Ebola Outbreak Killed 5000 Gorillas
Magdalena Bermejo, José Domingo Rodríguez‐Teijeiro, Germán Illera et al. · Science · 2006 · 398 citations
Veterinary Medicine, Infectious Disease Control, Infectious Diseases +17